Alveolar 0 8 0 8 B-chronic_disease
haemorrhage 9 20 9 20 I-chronic_disease
( 21 22 21 22 O
by 22 24 22 24 O
bronchoalveolar 25 40 25 40 B-treatment
lavage 41 47 41 47 I-treatment
) 47 48 47 48 O

Any 0 3 49 52 O
patients 4 12 53 61 O
with 13 17 62 66 O
a 18 19 67 68 O
known 20 25 69 74 O
hypersensitivity 26 42 75 91 O
to 43 45 92 94 O
reslizumab 46 56 95 105 B-treatment
or 57 59 106 108 O
any 60 63 109 112 O
of 64 66 113 115 O
its 67 70 116 119 O
excipients 71 81 120 130 O

Cardiomyopathy 0 14 131 145 B-chronic_disease
( 15 16 146 147 O
established 16 27 147 158 O
by 28 30 159 161 O
echocardiography 31 47 162 178 O
or 48 50 179 181 O
MRI 51 54 182 185 O
) 54 55 185 186 O

Glomerulonephritis 0 18 187 205 B-chronic_disease
( 19 20 206 207 O
haematuria 20 30 207 217 O
, 30 31 217 218 O
red 32 35 219 222 O
cell 36 40 223 227 O
casts 41 46 228 233 O
, 46 47 233 234 O
proteinuria 48 59 235 246 O
) 59 60 246 247 O

If 0 2 248 250 O
female 3 9 251 257 B-gender
and 10 13 258 261 O
of 14 16 262 264 O
child 17 22 265 270 O
- 22 23 270 271 O
bearing 23 30 271 278 O
potential 31 40 279 288 O
, 40 41 288 289 O
must 42 46 290 294 O
have 47 51 295 299 O
negative 52 60 300 308 B-pregnancy
pregnancy 61 70 309 318 I-pregnancy
test 71 75 319 323 O
and 76 79 324 327 O
must 80 84 328 332 O
adhere 85 91 333 339 B-contraception_consent
to 92 94 340 342 I-contraception_consent
acceptable 95 105 343 353 I-contraception_consent
method 106 112 354 360 I-contraception_consent
of 113 115 361 363 I-contraception_consent
contraception 116 129 364 377 I-contraception_consent
( 130 131 378 379 O
with 131 135 379 383 O
< 136 137 384 385 O
1 137 138 385 386 B-upper_bound
% 138 139 386 387 I-upper_bound
failure 140 147 388 395 B-clinical_variable
rate 148 152 396 400 I-clinical_variable
) 152 153 400 401 O
during 154 160 402 408 O
the 161 164 409 412 O
study 165 170 413 418 O
and 171 174 419 422 O
for 175 178 423 426 O
four 179 183 427 431 B-upper_bound
months 184 190 432 438 I-upper_bound
after 191 196 439 444 O
the 197 200 445 448 O
study 201 206 449 454 O

Immunosuppressive 0 17 455 472 B-treatment
therapy 18 25 473 480 I-treatment
: 25 26 480 481 O
If 27 29 482 484 O
receiving 30 39 485 494 O
immunosuppressive 40 57 495 512 B-treatment
therapy 58 65 513 520 I-treatment
( 66 67 521 522 O
including 67 76 522 531 O
methotrexate 77 89 532 544 B-treatment
, 89 90 544 545 O
azathioprine 91 103 546 558 B-treatment
, 103 104 558 559 O
or 105 107 560 562 O
mycophenolate 108 121 563 576 B-treatment
mofetil 122 129 577 584 I-treatment
, 129 130 584 585 O
but 131 134 586 589 O
excluding 135 144 590 599 O
restricted 145 155 600 610 O
medications 156 167 611 622 O
below 168 173 623 628 O
) 173 174 628 629 O
the 175 178 630 633 O
dosage 179 185 634 640 O
must 186 190 641 645 O
be 191 193 646 648 O
stable 194 200 649 655 O
for 201 204 656 659 O
the 205 208 660 663 O
4 209 210 664 665 B-upper_bound
weeks 211 216 666 671 I-upper_bound
prior 217 222 672 677 I-upper_bound
to 223 225 678 680 O
visit 226 231 681 686 O
1 232 233 687 688 O
and 234 237 689 692 O
during 238 244 693 699 O
the 245 248 700 703 O
study 249 254 704 709 O
( 255 256 710 711 O
dose 256 260 711 715 O
reductions 261 271 716 726 O
for 272 275 727 730 O
safety 276 282 731 737 O
reasons 283 290 738 745 O
will 291 295 746 750 O
be 296 298 751 753 O
permitted 299 308 754 763 O
) 308 309 763 764 O

Male 0 4 765 769 B-gender
or 5 7 770 772 I-gender
female 8 14 773 779 I-gender
subjects 15 23 780 788 I-gender

Malignancy 0 10 789 799 B-cancer

Neuropathy 0 10 800 810 B-chronic_disease
, 10 11 810 811 O
mono 12 16 812 816 O
or 17 19 817 819 O
poly 20 24 820 824 O
( 25 26 825 826 O
motor 26 31 826 831 O
deficit 32 39 832 839 O
or 40 42 840 842 O
nerve 43 48 843 848 O
conduction 49 59 849 859 O
abnormality 60 71 860 871 O
) 71 72 871 872 O

Palpable 0 8 873 881 B-chronic_disease
purpura 9 16 882 889 I-chronic_disease

Parasitic 0 9 890 899 B-chronic_disease
disease 10 17 900 907 I-chronic_disease

Patients 0 8 908 916 O
who 9 12 917 920 O
are 13 16 921 924 O
currently 17 26 925 934 O
receiving 27 36 935 944 O
or 37 39 945 947 O
have 40 44 948 952 O
previously 45 55 953 963 O
received 56 64 964 972 O
reslizumab 65 75 973 983 B-treatment
or 76 78 984 986 O
any 79 82 987 990 O
other 83 88 991 996 O
type 89 93 997 1001 O
of 94 96 1002 1004 O
anti 97 101 1005 1009 B-treatment
- 101 102 1009 1010 I-treatment
interleukin 102 113 1010 1021 I-treatment
therapy 114 121 1022 1029 I-treatment
( 122 123 1030 1031 O
i.e. 123 127 1031 1035 O
mepolizumab 128 139 1036 1047 B-treatment
, 139 140 1047 1048 O
lebrikizumab 141 153 1049 1061 B-treatment
etc 154 157 1062 1065 O
. 157 158 1065 1066 O
) 158 159 1066 1067 O
within 160 166 1068 1074 O
the 167 170 1075 1078 O
last 171 175 1079 1083 O
three 176 181 1084 1089 O
months 182 188 1090 1096 O

Pregnant 0 8 1097 1105 B-pregnancy
or 9 11 1106 1108 O
nursing 12 19 1109 1116 O

Pulmonary 0 9 1117 1126 B-chronic_disease
infiltrates 10 21 1127 1138 I-chronic_disease
, 21 22 1138 1139 O
non 23 26 1140 1143 O
- 26 27 1143 1144 O
fixed 27 32 1144 1149 O

Subjects 0 8 1150 1158 O
who 9 12 1159 1162 O
have 13 17 1163 1167 O
received 18 26 1168 1176 O
a 27 28 1177 1178 O
cyclophosphamide 29 45 1179 1195 B-treatment
( 46 47 1196 1197 I-treatment
CYC 47 50 1197 1200 I-treatment
) 50 51 1200 1201 I-treatment
induction 52 61 1202 1211 I-treatment
regimen 62 69 1212 1219 I-treatment
may 70 73 1220 1223 O
be 74 76 1224 1226 O
included 77 85 1227 1235 O
a 86 87 1236 1237 O
minimum 88 95 1238 1245 O
of 96 98 1246 1248 O
2 99 100 1249 1250 B-lower_bound
weeks 101 106 1251 1256 I-lower_bound
after 107 112 1257 1262 O
the 113 116 1263 1266 O
last 117 121 1267 1271 O
dose 122 126 1272 1276 O
of 127 129 1277 1279 O
daily 130 135 1280 1285 O
oral 136 140 1286 1290 O
CYC 141 144 1291 1294 O
, 144 145 1294 1295 O
or 146 148 1296 1298 O
3 149 150 1299 1300 O
weeks 151 156 1301 1306 O
after 157 162 1307 1312 O
the 163 166 1313 1316 O
last 167 171 1317 1321 O
dose 172 176 1322 1326 O
of 177 179 1327 1329 O
pulsed 180 186 1330 1336 O
IV 187 189 1337 1339 B-treatment
CYC 190 193 1340 1343 I-treatment
prior 194 199 1344 1349 O
to 200 202 1350 1352 O
visit 203 208 1353 1358 O
1 209 210 1359 1360 O
, 210 211 1360 1361 O
if 212 214 1362 1364 O
their 215 220 1365 1370 O
total 221 226 1371 1376 O
WBC 227 230 1377 1380 B-clinical_variable
is 231 233 1381 1383 O
â‰¥4x109 234 240 1384 1390 O
/ 240 241 1390 1391 I-lower_bound
L 241 242 1391 1392 I-lower_bound
prior 243 248 1393 1398 O
to 249 251 1399 1401 O
visit 252 257 1402 1407 O
1 258 259 1408 1409 O

Subjects 0 8 1410 1418 O
who 9 12 1419 1422 O
have 13 17 1423 1427 O
received 18 26 1428 1436 O
a 27 28 1437 1438 O
methotrexate 29 41 1439 1451 B-treatment
, 41 42 1451 1452 O
azathioprine 43 55 1453 1465 B-treatment
, 55 56 1465 1466 O
or 57 59 1467 1469 O
mycophenolate 60 73 1470 1483 B-treatment
mofetil 74 81 1484 1491 I-treatment
induction 82 91 1492 1501 O
regimen 92 99 1502 1509 O
may 100 103 1510 1513 O
be 104 106 1514 1516 O
included 107 115 1517 1525 O
if 116 118 1526 1528 O
on 119 121 1529 1531 O
a 122 123 1532 1533 O
stable 124 130 1534 1540 O
dose 131 135 1541 1545 O
for 136 139 1546 1549 O
at 140 142 1550 1552 O
least 143 148 1553 1558 O
4 149 150 1559 1560 B-lower_bound
weeks 151 156 1561 1566 I-lower_bound
prior 157 162 1567 1572 I-lower_bound
to 163 165 1573 1575 O
visit 166 171 1576 1581 O
1 172 173 1582 1583 O

Taking 0 6 1584 1590 O
cyclophosphamide 7 23 1591 1607 B-treatment

Wegener 0 7 1608 1615 B-chronic_disease
's 7 9 1615 1617 I-chronic_disease
Granulomatosis 10 24 1618 1632 I-chronic_disease

subjects 0 8 1633 1641 O
who 9 12 1642 1645 O
have 13 17 1646 1650 O
been 18 22 1651 1655 O
diagnosed 23 32 1656 1665 O
with 33 37 1666 1670 O
EGPA 38 42 1671 1675 B-chronic_disease
for 43 46 1676 1679 O
at 47 49 1680 1682 O
least 50 55 1683 1688 O
6 56 57 1689 1690 B-lower_bound
months 58 64 1691 1697 I-lower_bound
based 65 70 1698 1703 O
on 71 73 1704 1706 O
the 74 77 1707 1710 O
history 78 85 1711 1718 O
or 86 88 1719 1721 O
presence 89 97 1722 1730 O
of 98 100 1731 1733 O
: 100 101 1733 1734 O
asthma 102 108 1735 1741 B-chronic_disease
plus 109 113 1742 1746 O
eosinophilia 114 126 1747 1759 B-clinical_variable
( 127 128 1760 1761 O
> 128 129 1761 1762 O
1.0x109 129 136 1762 1769 B-lower_bound
/ 136 137 1769 1770 I-lower_bound
L 137 138 1770 1771 I-lower_bound
and/or 139 145 1772 1778 O
> 146 147 1779 1780 O
10 147 149 1780 1782 B-lower_bound
% 149 150 1782 1783 I-lower_bound
of 151 153 1784 1786 O
leucocytes 154 164 1787 1797 B-clinical_variable
) 164 165 1797 1798 O
plus 166 170 1799 1803 O
at 171 173 1804 1806 O
least 174 179 1807 1812 O
two 180 183 1813 1816 O
of 184 186 1817 1819 O
the 187 190 1820 1823 O
following 191 200 1824 1833 O
additional 201 211 1834 1844 O
features 212 220 1845 1853 O
of 221 223 1854 1856 O
EGPA 224 228 1857 1861 O

